Industry News
Biotechnology Industry News

Have we passed the peak of biotech…
Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the figures.
ctDNA assays are changing how…
ctDNA assays are changing how hematologic cancers are monitored, from MRD detection to clinical trial design.
Half a year after being spurned by…
Half a year after being spurned by the FDA and following several rounds of deep layoffs, IO Biotech has decided to close its doors for good.
Ambrosia Biosciences is aiming to…
Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million series B round.
Eli Lilly has gone big in the name…
Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals and its sleep disorder pipeline.
A phase 3 trial of AstraZeneca’s…
A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the company’s ability to expand beyond the children served by its existing drug.
Lipella Pharmaceuticals’…
Lipella Pharmaceuticals’ ambition to develop the first treatment for an inflammatory mouth condition has reached the end of the road, with the biotech filing for bankruptcy.
The New Jersey pharma is tapping…
The New Jersey pharma is tapping Infinimmune to hunt for antibodies for as-of-yet undisclosed targets.
Astellas Pharma has become the…
Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune disease that still lacks any dedicated medicines.
One of the world’s leading…
One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life Sciences VI (BLXS VI) fund, which is 40% larger than its predecessor.
Autoimmune specialist Aurinia,…
Autoimmune specialist Aurinia, which named Kevin Tang as its new CEO last week, is acquiring Kezar after the latter company received promising feedback from the FDA. Tang previously made an unsuccessful attempt in 2024 to
Royalty Pharma has made another…
Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune disease treatment, with
Connect Biopharma has reported…
Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is better than Dupixent.
Despite the primary endpoint hit,…
Despite the primary endpoint hit, the candidate's inability to meet investors’ expectations cast a shadow over the results.
Kardigan’s tonlamarsen reduced a…
Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure.
Biogen’s lupus drug candidate…
Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of the autoimmune disease.
Kailera Therapeutics—one of the…
Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.
In the early 1960s, Norwegian…
In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally discovered a lipoprotein with perplexing properties.
KBP Biosciences is looking to…
KBP Biosciences is looking to reclaim ownership of the ill-fated heart drug ocedurenone from Novo Nordisk following a botched $1.3 billion deal and fraud allegations, Fierce Biotech has learned.
Eli Lilly and AI-powered…
Eli Lilly and AI-powered clinical-stage biotech Insilico Medicine have announced a back-loaded, $2.75 billion biobucks drug discovery collaboration that will extend the Big Pharma company’s access to Insilico’s AI engine to pursue novel therapeutics.

